Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of CR1, CLU and PICALM confer susceptibility of Alzheimer's disease in a southern Chinese population.
|
22015308 |
2012 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We have followed-up on the recent genome-wide association (GWA) of the clusterin gene (CLU) with increased risk for Alzheimer disease (AD), by performing an unbiased resequencing of all CLU coding exons and regulatory regions in an extended Flanders-Belgian cohort of Caucasian AD patients and control individuals (n = 1930).
|
22248099 |
2012 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To explore mechanisms that may underlie associations between Alzheimer's disease (AD) and schizophrenia risk CLU gene and verbal memory, one of the most affected cognitive domains in both conditions, we studied DNA methylation in a region between AD-associated SNPs rs9331888 and rs9331896 in 72 healthy individuals and 73 schizophrenia patients.
|
30599442 |
2019 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
These findings add to the evidence that the CLU gene may represent a potential therapeutic target for slowing disease progression in AD.
|
26899953 |
2016 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
This article reviews possible links between AD pathogenic factors such as AβPP/Aβ and tau; novel risk genes including clusterin, phosphatidylinositol-binding clathrin assembly protein, complement receptor 1, bridging integrator 1, ATP-binding cassette transporter 7, membrane-spanning 4-domains subfamily A, CD2-associated protein, sialic acid-binding immunoglobulin-like lectin, and ephrin receptor A1; metabolic changes including insulin resistance and hypercholesterolemia; lipid changes including alterations in brain phospholipids, cholesterol and ceramides; glial changes affecting microglia and astrocytes; alterations in brain iron metallome and oxidative stress; and slow excitotoxicity.
|
23481689 |
2013 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In a multicenter case-control association study, we studied the SNPs rs11136000 (clusterin, CLU), rs541458 (phosphatidylinositol binding clatrin assembly protein, PICALM), and rs1554948 (transcription factor A, and tyrosine kinase, non-receptor, 1, TNK1) according to the three age groups 50-65 years (group 1), 66-80 years (group 2), and 80+ years (group 3) in 569 older subjects without cognitive impairment (NoCI) and 520 Alzheimer's disease (AD) patients.
|
28631188 |
2018 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals.
|
20534741 |
2010 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
These loci are in or near-novel AD genes including BIN1, CR1, CLU, phosphatidylinositol-binding clathrin assembly protein (PICALM), CD33, EPHA1, MS4A4/MS4A6, ABCA7, CD2AP, SORL1, HLA-DRB5/DRB1, PTK2B, SLC24A4-RIN3, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2, CASS4, and TRIP4 and each has small effects on risk of AD (relative risks of 1.1-1.3).
|
25311924 |
2014 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Although the exact contribution of these variants to altered AD risk is unclear, some have been linked to altered <i>CLU</i> expression at both mRNA and protein levels, altered cognitive and memory function, and altered brain structure.
|
30872998 |
2019 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The present study failed to detect any association between the SNP of the CLU gene and AD.
|
21447104 |
2011 |
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Plasma clusterin levels were not related to the risk of incident AD during total follow-up (adjusted HR, 1.00; 95% CI, 0.85-1.17; P for trend = .77) or within 3 years of baseline (adjusted HR, 1.09; 95% CI, 0.84-1.42; P for trend = .65).
|
21467285 |
2011 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
AAPs, such as apolipoprotein E (ApoE) or apolipoprotein J (ApoJ) have been strongly implicated in the pathogenesis of AD in vitro and in vivo.
|
16972883 |
2006 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Changes in the CLU gene locus are highly associated with Alzheimer disease, and many therapy-resistant cancers over-express CLU.
|
27978767 |
2017 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease.
|
21347408 |
2011 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB1, HLA-DRB4, INPP5D, MEF2C, MS4A4A, MS4A4E, MS4A6E, NME8, PICALM, PLD3, PTK2B, RIN3, SLC24A4, SORL1, and ZCWPW1 genes.
|
28199971 |
2017 |
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
TRPM-2/clusterin is induced de novo during the regression of the prostate and other hormone-dependent tissues after hormone ablation, and is over-expressed in several human neurodegenerative diseases including Alzheimer's disease, epilepsy and retinitis pigmentosa.
|
8181474 |
1994 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Clusterin (apolipoprotein J), a multifunctional protein involved in amyloidogenesis in Alzheimer's disease, was studied immunohistochemically in both human transmissible spongiform encephalopathies (TSEs) and a mouse model of human TSE.
|
11907798 |
2002 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
No association was observed for CLU and PICALM with AD.
|
28558900 |
2017 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to examine whether the variants of some candidate genes involved in the development of AD, namely BIN1 (rs744373), CLU (rs11136000), CR1 (rs3818361), and PICALM (rs3851179), are related to several disorders of glucose metabolism-gestational diabetes (GDM), T2DM and impaired glucose tolerance (IGT).
|
28316001 |
2017 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
In the present study, nsSNPs in CLU, PICALM and BIN1 genes were screened for their functional impact on concerned proteins and their plausible role in Alzheimer disease (AD) susceptibility.
|
22960267 |
2013 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Unadjusted, CLU (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.85-0.96 for single-nucleotide polymorphism [SNP] rs11136000), CR1 (OR, 1.14; 95% CI, 1.07-1.22; SNP rs3818361), and PICALM (OR, 0.89; 95% CI, 0.84-0.94, SNP rs3851179) were associated with AD in white individuals.
|
20697030 |
2010 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Clusterin variants are not associated with southern Chinese patients with Alzheimer's disease.
|
24958191 |
2014 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Plasma clusterin was not influenced by genotype in the MCI and AD subjects, although in control subjects plasma clusterin was lower in the TT vs. TC genotypes (157.6 ± 53.4 vs. 188.6 ± 30.5 μg/ml; p<0.05).
|
24117116 |
2013 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Recent studies showed the Clusterin gene (CLU) is associated with Alzheimer's disease (AD).
|
25703218 |
2015 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although SGP-2 transcripts, and hence pTB16, were recently shown to be increased in neurodegenerative diseases such as scrapie in hamsters and Alzheimer disease in humans, our observations with brain tumors and epilepsy are suggestive of a role for pTB16 in neuropathologies in general and support the hypothesis of its involvement in tissue remodeling and cell death.
|
1924317 |
1991 |